Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Published: |
Springer
2019
|